Literature DB >> 15389644

Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells.

Krisztina Kisfalvi1, Sushovan Guha, Enrique Rozengurt.   

Abstract

Neurotensin (NT) and epidermal growth factor (EGF) induced rapid extracellular-regulated protein kinase (ERK) activation through different signaling pathways in the K-Ras mutated human pancreatic carcinoma cell lines PANC-1 and MIA PaCa-2. NT stimulated ERK activation via a protein kinase C (PKC)-dependent (but EGF receptor-independent) pathway in PANC-1 and MIA PaCa-2 cells, whereas EGF promoted ERK activation through a PKC-independent pathway in these cells. Concomitant stimulation of these cells with NT and EGF induced a striking increase in the duration of ERK pathway activation as compared with that obtained in cells treated with each agonist alone. Stimulation with NT + EGF promoted synergistic stimulation of DNA synthesis and anchorage-independent growth. Addition of the MEK inhibitor U0126, either prior to stimulation with NT + EGF or 2 h after stimulation with NT + EGF prevented the synergistic increase in DNA synthesis and suppressed the sustained phase of ERK activation. Furthermore, treatment with the selective PKC inhibitor GF-1 converted the sustained ERK activation in response to NT and EGF into a transient signal and also abrogated the synergistic increase in DNA synthesis. Collectively, our results suggest that the sustained phase of ERK signaling mediates the synergistic effects of NT and EGF on DNA synthesis in pancreatic cancer cells. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389644     DOI: 10.1002/jcp.20187

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  26 in total

1.  Purinergic receptors in the endocrine and exocrine pancreas.

Authors:  I Novak
Journal:  Purinergic Signal       Date:  2007-12-11       Impact factor: 3.765

Review 2.  Role of protein kinase D signaling in pancreatic cancer.

Authors:  Sushovan Guha; Suebpong Tanasanvimon; James Sinnett-Smith; Enrique Rozengurt
Journal:  Biochem Pharmacol       Date:  2010-07-16       Impact factor: 5.858

3.  Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.

Authors:  Enrique Rozengurt; James Sinnett-Smith; Krisztina Kisfalvi
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

4.  Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.

Authors:  Fang Hao; Qinhong Xu; Yinglan Zhao; Jan V Stevens; Steven H Young; James Sinnett-Smith; Enrique Rozengurt
Journal:  Mol Cancer Res       Date:  2017-03-30       Impact factor: 5.852

Review 5.  Protein kinase D signaling: multiple biological functions in health and disease.

Authors:  Enrique Rozengurt
Journal:  Physiology (Bethesda)       Date:  2011-02

Review 6.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

7.  Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.

Authors:  Alessia Di Florio; Veronica Sancho; Paola Moreno; Gianfranco Delle Fave; Robert T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-12-04

8.  Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells.

Authors:  Krisztina Kisfalvi; Cliff Hurd; Sushovan Guha; Enrique Rozengurt
Journal:  J Cell Physiol       Date:  2010-05       Impact factor: 6.384

9.  Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.

Authors:  James Sinnett-Smith; Krisztina Kisfalvi; Robert Kui; Enrique Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  2012-11-15       Impact factor: 3.575

10.  SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.

Authors:  Terry W Moody; Daniel C Chan; Samuel A Mantey; Paola Moreno; Robert T Jensen
Journal:  Life Sci       Date:  2014-02-02       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.